No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

A Hollestelle; FH Van Der Baan; A Berchuck; SE Johnatty; KK Aben; BA Agnarsson; K Aittomäki; E Alducci; IL Andrulis; H Anton-Culver; NN Antonenkova; AC Antoniou; C Apicella; V Arndt; N Arnold; BK Arun; B Arver; A Ashworth; L Baglietto; R Balleine; EV Bandera; D Barrowdale; YT Bean; L Beckmann; MW Beckmann; J Benitez; A Berger; R Berger; B Beuselinck; M Bisogna; L Bjorge; C Blomqvist; NV Bogdanova; A Bojesen; SE Bojesen; MK Bolla; B Bonanni; JS Brand; H Brauch; H Brenner; L Brinton; A Brooks-Wilson; F Bruinsma; J Brunet; T Brüning; A Budzilowska; CH Bunker; B Burwinkel; R Butzow; SS Buys; MA Caligo; I Campbell; J Carter; J Chang-Claude; SJ Chanock; KBM Claes; JM Collée; LS Cook; FJ Couch; A Cox; D Cramer; SS Cross; JM Cunningham; C Cybulski; K Czene; F Damiola; A Dansonka-Mieszkowska; H Darabi; M De La Hoya; A Defazio; J Dennis; P Devilee; EM Dicks; O Diez; JA Doherty; SM Domchek; CM Dorfling; T Dörk; IDS Silva; A Du Bois; M Dumont; AM Dunning; M Duran; DF Easton; D Eccles; RP Edwards; H Ehrencrona; B Ejlertsen; AB Ekici; SD Ellis; C Engel; M Eriksson; PA Fasching; L Feliubadalo; J Figueroa; D Flesch-Janys; O Fletcher; A Fontaine; S Fortuzzi; F Fostira

Journal article

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

A Hollestelle, FH Van Der Baan, A Berchuck, SE Johnatty, KK Aben, BA Agnarsson, K Aittomäki, E Alducci, IL Andrulis, H Anton-Culver, NN Antonenkova, AC Antoniou, C Apicella, V Arndt, N Arnold, BK Arun, B Arver, A Ashworth, L Baglietto, R Balleine Show all

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2016

DOI: 10.1016/j.ygyno.2015.04.034

Abstract

Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 brea..

View full abstract

University of Melbourne Researchers

Fiona Bruinsma Author

Graham Giles Author

Catriona McLean Author

Roger Milne Author

Related Projects (6)

NIH AUSTRALIAN BREAST CANCER FAMILY REGISTRY SOUTHEY-HOPPER

DESCRIPTION (provided by applicant): The broad objective of the Breast Cancer Family Registry (Breast CFR) is to establish and maintain a hy..

Epidemiology of chronic disease, health interventions and DNA studies

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

REDUCING THE BURDEN OF BREAST CANCER FOR AUSTRALIAN WOMEN AND THEIR FAMILIES

Grants

Awarded by Mayo Foundation for Medical Education and Research

Funding Acknowledgements

The COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 HEALTH-F2-2009-223175). The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk/. Funding for the project was provided by the Wellcome Trust under award 076113.r G.C.-T. and P.M.W. are supported by the National Health and Medical Research Council; P.A.F. is supported by the Deutsche Krebshilfe; B.K. holds an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN); K.-A.P. is an Australian National Breast Cancer Foundation Fellow; and A.B. holds the Barbara Thomason Ovarian Cancer Research Professorship from the American Cancer Society (SIOP-06-090-06). R. Balleine was a Cancer Institute NSW Clinical Research Fellow.r OCAC, in particular, acknowledges D. Bowtell, A. deFazio, D. Gertig, A. Green, P. Parsons, N. Hayward and D. Whiteman (AUS); G. Peuteman, T. Van Brussel and D. Smeets (BEL); U. Eilber and T. Koehler (GER); L. Gacucova (HMO); P. Schtirmann, F. Kramer, W. Zheng, T.-W. Park Simon, K. Beer-Grondke and D. Schmidt (HJO); Sharon Windebank, Christopher Hilker and Jason Vollenweider (MAY); the state cancer registries of AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK OR, PA, RI, SC, TN, TX, VA, WA, and WY (NHS); L. Paddock, M. King, U. Chandran, A. Samoila, and Y. Bensman (NJO); L. Brinton, M. Sherman, A. Hutchinson, N. SzeszeniaDabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao and M. Stagner (POL); C. Luccarini, P. Harrington, the SEARCH team and ECRIC (SEA); the Scottish Gynaecological Clinical Trails group and SCOTROCI investigators (SRO); W -H. Chow and Y -T. Gao (SWH); I. Jacobs, M. Widschwendter, E. Wozniak, N. Balogun, A. Ryan and J. Ford (UKO); and Carole Pye (UKR). r Funding of the constituent OCAC studies was provided by the American Cancer Society (CRTG-00-196-01-CCE); the California Cancer Research Program (00-01389V-20170, N01-CN25403, 2110200); the Canadian Institutes for Health Research; Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124, C536/A13086, C536/A6689); the Celma Mastry Ovarian Cancer Foundation the Danish Cancer Society (94-222-52); ELAN Funds of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Central Hospital Research Fund; Imperial Experimental Cancer Research Centre (C1312/A15589); the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; the L & S Milken Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell Park Cancer Institute Alliance Foundation; the US National Cancer Institute (K07-CA095666, K07-CA143047, K22-CA138563, N01-CN55424, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087696, P3O-CA15083, P5O-CA105009, P50-CA136393, R01-CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01-CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA063678, R01-CA063682, R01-CA064277, R01-CA067262, R01-CA071766, R01-CA076016, R01-CA080978, R01-CA087538, R01-CA092044, R01-095023, R01-CA106414, R01-CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01-CA149429, R01CA83918, R03-CA113148, R03-CA115195, R37-CA070867, R37-CA70867, U01-CA069417, U01-CA071966 and Intramural research funds); the US Army Medical Research and Material Command (DAMD17-98-1-8659, DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669, W81XWH-07-0449); the National Health and Medical Research Council of Australia (199600 and 400281); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01 GB 9401); the state of Baden-Wurttemberg through Medical Faculty of the University of Ulm (P.685); the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the Lon V.r Smith Foundation (LVS-39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial College London, University College Hospital "Women's Health Theme" and the Royal Marsden Hospital; and WorkSafeBC.